Chemotherapy-Induced Oral Mucositis Guidelines

1. Mulcahy N. ‘New standard of care' for oral mucositis. Medscape Medical News. October 30, 2012. [Full Text].

2. Mayo Clinic. Doxepin hydrochloride in treating oral mucositis pain in patients with head and neck cancer undergoing radiation therapy with or without chemotherapy. Available at http://tinyurl.com/ClinicalTrialDoxepin. Accessed: November 19, 2012.

3. [Guideline] Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020 Oct 1. 126 (19):4423-4431. [QxMD MEDLINE Link]. [Full Text].

4. Scully C, Sonis S, Diz PD. Oral mucositis. Oral Dis. 2006 May. 12(3):229-41. [QxMD MEDLINE Link].

5. [Guideline] Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014. 120:1453-61. [QxMD MEDLINE Link].

6. Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol. 2006 Nov 20. 24(33):5194-200. [QxMD MEDLINE Link].

7. Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010 Jan 1. 116(1):210-5. [QxMD MEDLINE Link].

8. Sonis S, Andreotta PW, Lyng G. On the pathogenesis of mTOR inhibitor-associated stomatitis (mIAS)-studies using an organotypic model of the oral mucosa. Oral Dis. 2017 Apr. 23 (3):347-352. [QxMD MEDLINE Link].

9. Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017 May. 18 (5):654-662. [QxMD MEDLINE Link].

10. Russi EG, Raber-Durlacher JE, Sonis ST. Local and systemic pathogenesis and consequences of regimen-induced inflammatory responses in patients with head and neck cancer receiving chemoradiation. Mediators Inflamm. 2014. 2014:518261. [QxMD MEDLINE Link].

11. Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant. 2005 May. 11 (5):383-8. [QxMD MEDLINE Link].

12. Shajahan J, Pillai PS, Jayakumar KN. A Prospective Comparative Study of the Toxicity Profile of 5-Flurouracil, Adriamycin, Cyclophosphamide Regime VS Adriamycin, Paclitaxel Regime in Patients with Locally Advanced Breast Carcinoma. J Clin Diagn Res. 2015 Dec. 9 (12):FC01-6. [QxMD MEDLINE Link].

13. Vagliano L, Feraut C, Gobetto G, Trunfio A, Errico A, Campani V, et al. Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT--results of a multicentre study. Bone Marrow Transplant. 2011 May. 46 (5):727-32. [QxMD MEDLINE Link].

14. Raber-Durlacher JE, Laheij AM, Epstein JB, Epstein M, Geerligs GM, Wolffe GN, et al. Periodontal status and bacteremia with oral viridans streptococci and coagulase negative staphylococci in allogeneic hematopoietic stem cell transplantation recipients: a prospective observational study. Support Care Cancer. 2013 Jun. 21 (6):1621-7. [QxMD MEDLINE Link].

15. Cutler C, Li S, Kim HT, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant. 2005 May. 11(5):383-8. [QxMD MEDLINE Link].

16. Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol. 2007 May. 5 (5):231-5. [QxMD MEDLINE Link].

17. [Guideline] National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. National Cancer Institute. Available at https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf. 2017 Nov 27; Accessed: 2022 Mar 31.

18. Stiff PJ, Erder H, Bensinger WI, et al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 2006 Feb. 37(4):393-401. [QxMD MEDLINE Link].

19. Yokota T, Ogawa T, Takahashi S, Okami K, Fujii T, Tanaka K, et al. Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study. BMC Cancer. 2017 May 5. 17 (1):314. [QxMD MEDLINE Link]. [Full Text].

20. Brizel DM, Murphy BA, Rosenthal DI, et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol. 2008 May 20. 26(15):2489-96. [QxMD MEDLINE Link].

21. Vadhan-Raj S, Trent J, Patel S, et al. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med. 2010 Sep 21. 153(6):358-67. [QxMD MEDLINE Link].

22. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004 Dec 16. 351(25):2590-8. [QxMD MEDLINE Link].

23. Elad S, Raber-Durlacher JE, Brennan MT, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015 Jan. 23 (1):223-36. [QxMD MEDLINE Link].

Nathaniel S Treister, DMD, DMSc Associate Professor, Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine; Associate Surgeon and Division Chief, Division of Oral Medicine and Dentistry, Brigham and Women's Hospital

Nathaniel S Treister, DMD, DMSc is a member of the following medical societies: American Academy of Oral Medicine, American Dental Association

Disclosure: Nothing to disclose.

Vidya Sankar, DMD, MHS, FDS, RCSEd Associate Surgeon, Division of Oral Medicine and Dentistry, Brigham and Women’s Hospital

Vidya Sankar, DMD, MHS, FDS, RCSEd is a member of the following medical societies: American Academy of Oral Medicine

Disclosure: Consultant, however no monies have been recieved as of yet. for: OraPharma.

David F Butler, MD Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, Association of Military Dermatologists, Phi Beta Kappa, Texas Dermatological Society

Disclosure: Nothing to disclose.

Drore Eisen, MD, DDS Consulting Staff, Dermatology of Southwest Ohio

Drore Eisen, MD, DDS is a member of the following medical societies: American Academy of Dermatology, American Academy of Oral Medicine, American Dental Association

Disclosure: Nothing to disclose.

Jeff Burgess, DDS, MSD (Retired) Clinical Assistant Professor, Department of Oral Medicine, University of Washington School of Dental Medicine; (Retired) Attending in Pain Center, University of Washington Medical Center; (Retired) Private Practice in Hawaii and Washington; Director, Oral Care Research Associates

Disclosure: Nothing to disclose.

Ponciano D Cruz, Jr, MD Professor and Vice-Chair, Paul R Bergstresser Chair, Department of Dermatology, University of Texas Southwestern Medical Center

Ponciano D Cruz, Jr, MD is a member of the following medical societies: Texas Medical Association

Disclosure: Received consulting fee from RCTS for independent contractor; Received honoraria from Mary Kay Cosmetics for consulting; Received grant/research funds from Galderma for principal investigator.

Sook-Bin Woo, DMD, MS Associate Professor, Chief, Division of Oral Medicine and Oral Pathology, Department of Oral Medicine and Diagnostic Services, Harvard School of Dental Medicine; Chief of Clinical Affairs, Brigham and Women's Hospital; Consultant, Dana Farber Cancer Institute, Beth Israel/Deaconess Medical Center

Sook-Bin Woo, DMD, MS is a member of the following medical societies: American Academy of Oral and Maxillofacial Pathology, American Academy of Oral Medicine, American Dental Association

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article